return to F index

return to index page

PTD - 231

Test Directory - Flecanide



Clinical Indications

Flecanide is used for the treatment and prophylaxis of supraventricular tachycardia, including AV nodal and AV re-entrant tachycardia and atrial fibrillation in patients with normal or near-normal left ventricular function

Drug Kinetics

The drug is well absorbed orally. Plasma half-life averages 20 hours (range 12 to 27 hours) in adults, although in children it has been reported to be eight hours. Steady-state levels are achieved in three to five days. Since 10% to 50% of the drug is eliminated in the urine as unchanged drug, impaired renal function will significantly prolong the plasma half-life. Clearance of flecainide can be accelerated by phenobarbital and rifampin. There are no significant metabolites of flecainide. Co-administration with digoxin increases serum digoxin by 20%

Request Form

Combined Pathology Blood form (Yellow/Black)


Referral test: Analysed by the Protein Reference Unit, Sheffield if specific criteria met.

Specific Criteria

Requested by Consultant or agreed with Consultant Biochemist

Patient Preparation

Samples should be collected before next dose (trough)

Turnaround Time

2 weeks




1 ml


Red top (plain) tube preferred.
Yellow top (SST) tube acceptable if sample separated within 12 hours.

Causes for Rejection

Not meeting specific criteria for analysis.

Target  Range

200 to 700 ug/L (timing of blood collection not critical)


Lab. Handling

Processing: Aliquot and store at 4C in separating fridge (CB39).
: FLEC and send or BPRO and save in separating freezer (CB40) at
-20C, saved frozen rack.

Version 1.0 / May 2014                                                                                                           Approved by: Consultant Biochemist